New T Cell Therapy reagent for mRNA delivery using Lipid Nanoparticles
28 May, 2021 | Newsletters
|Precision NanoSystems is proud to announce that the GenVoy-ILM™ T Cell Kit for mRNA is now available to enable lipid nanoparticle (LNP)-based ex vivo gene transfer into T cells. Scientists can now use mRNA-LNP to efficiently and reproducibly generate high yields of engineered primary human T cells using a simple workflow. |
Read the full press release here
One preparation is ready in under 5 minutes, and the resulting mRNA-LNPs can be seamlessly integrated into standard T cell culture workflows. The GenVoy-ILM T Cell Kit for mRNA and the NanoAssemblr® Spark™ enable the preparation of mRNA encapsulating LNP optimized for delivery to activated primary human T cells. It can be used at various stages of cell therapy research from discovery to preclinical development.
mRNA-LNP generated from the GenVoy-ILM T Cell Kit for mRNA leverage endogenous cellular uptake mechanisms
View the data
Webinar: Rethink T Cell Therapy with Lipid Nanoparticles
Learn more about how the GenVoy-ILM T Cell Kit for mRNA can empower your research.
• Review of current ex vivo gene delivery strategies for cell therapies
• Introduction of GenVoy lipid nanoparticle delivery platform
• Presentation of data in T cells comparing the GenVoy-ILM T Cell Kit for mRNA with electroporation
To watch the recording click here
|Request training or a demo |
Click here for sample testing
Click here for service support